on Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences' Abstract Accepted for SITC 2025 Meeting
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. This event will take place from March 12 to 14, 2025, in San Diego, CA, and also virtually.
The abstract, titled "DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma," will be presented by Dr. Alexey Stepanov from The Scripps Research Institute. The presentation is scheduled for March 12, 2025, from 5:10 p.m. to 6:45 p.m. PT.
Xenetic Biosciences focuses on developing immuno-oncology technologies for hard-to-treat cancers. The DNase platform aims to enhance treatment outcomes by targeting neutrophil extracellular traps in various cancers.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xenetic Biosciences, Inc. news